Up­dat­ed: FDA ad­comm backs ben­e­fits of Abec­ma and Carvyk­ti in ear­li­er pa­tients

An FDA ad­vi­so­ry com­mit­tee vot­ed on Fri­day that the ben­e­fits of two CAR-T ther­a­pies, Carvyk­ti and Abec­ma, out­weigh their risks in ear­li­er-stage mul­ti­ple myelo­ma pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER